Kyverna Therapeutics, Inc. $KYTX Shares Bought by Insight Holdings Group LLC

Key Points

• Insight Holdings Group LLC increased its stake in Kyverna Therapeutics by 8.3%, acquiring an additional 76,139 shares, bringing its total ownership to 989,054 shares, valued at approximately $1.9 million.
• Recent analyst activity shows a positive outlook for Kyverna Therapeutics, with a consensus rating of "Buy" and a target price increase from $5.00 to $10.00.
• Despite this, Kyverna Therapeutics' stock experienced a decline of 2.4%, trading at $3.63 with a market capitalization of $157 million.

Insight Holdings Group LLC increased its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 8.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 989,054 shares of the company's stock after purchasing an additional 76,139 shares during the quarter. Kyverna Therapeutics accounts for 0.1% of Insight Holdings Group LLC's holdings, making the stock its 25th largest holding. Insight Holdings Group LLC owned about 2.29% of Kyverna Therapeutics worth $1,909,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in Kyverna Therapeutics during the 1st quarter worth $137,000. Cubist Systematic Strategies LLC grew its stake in Kyverna Therapeutics by 31.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company's stock worth $132,000 after purchasing an additional 16,267 shares in the last quarter. Nuveen LLC acquired a new position in Kyverna Therapeutics during the 1st quarter worth $92,000. Peapod Lane Capital LLC acquired a new position in Kyverna Therapeutics during the 1st quarter worth $765,000. Finally, Bank of New York Mellon Corp grew its stake in Kyverna Therapeutics by 22.2% during the 1st quarter. Bank of New York Mellon Corp now owns 48,784 shares of the company's stock worth $94,000 after purchasing an additional 8,851 shares in the last quarter. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Trading Up 8.5%

Shares of Kyverna Therapeutics stock traded up $0.31 on Friday, hitting $3.94. The stock had a trading volume of 217,394 shares, compared to its average volume of 283,574. Kyverna Therapeutics, Inc. has a 52-week low of $1.78 and a 52-week high of $7.85. The stock has a market cap of $170.41 million, a price-to-earnings ratio of -1.07 and a beta of 3.07. The company's 50 day moving average price is $3.58 and its 200 day moving average price is $2.85.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.03. Analysts predict that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on KYTX shares. William Blair began coverage on Kyverna Therapeutics in a research note on Wednesday, August 20th. They set an "outperform" rating for the company. HC Wainwright lifted their price target on Kyverna Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, August 29th. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $16.60.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.